Abstract:Signal transducer and activator of transcription 3 (STAT3) is known to modulate expression related to cell transformation, proliferation and survival making it a significant target for cancer therapy. Recent research has also highlighted the crucial involvement of aberrant STAT3 activation in the pathogenesis of diabetic kidney disease (DKD). This paper aims to explore the therapeutic implications of targeting STAT3 in DKD, encompassing its structural characteristics, regulatory mechanisms of activity, pathological activation in DKD, and an overview of current research progress, with the objective of advancing understanding of DKD pathogenesis.